Boardroom Alpha
10-K primary document
APRE · Annual Report (Form 10-K) · Filed March 16, 2026

Aprea Therapeutics Inc10-K exhibit

apre-20251231xex10d4.htm

Exhibit 10.4

APREA THERAPEUTICS, INC.

2019 STOCK INCENTIVE PLAN

STOCK OPTION AWARD NOTICE

<Awardee Name>

You have been awarded an option to purchase shares of Common Stock of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Stock Incentive Plan (the “Plan”) and the Stock Option Agreement (together with this Award Notice, the “Agreement”). Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.

Option:You have been awarded an Option to purchase from the Company shares of its Common Stock, par value $0.001 per share (the “Common Stock”), subject to adjustment as provided in Section 4.2 of the Agreement as follows:

Options Granted

xxxx

Grant Price

$xxx

Option Date:<Date of Award>

Exercise Price:See above, subject to adjustment as provided in Section 4.2 of the Agreement.

Vesting Schedule:

Except as otherwise provided in the Plan, the Agreement or any other agreement between the Company or any of its Subsidiaries and Optionee, the Option shall vest and become exercisable as follows: (i) one quarter of the shares subject to the Option on the Option Date shall vest on the one-year anniversary of the Option Date and (ii) 1/36th of the shares subject to the Option on the Option Date shall vest thereafter on a monthly basis on each monthly anniversary of the Option Date, if, and only if, you are, and have been, continuously (except for any absence for vacation, leave, etc. in accordance with the Company's or its Subsidiaries' policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the date of this Agreement through and including the applicable vesting date.

Expiration Date:Except to the extent earlier terminated pursuant to Section 2.2 of the Agreement or earlier exercised pursuant to Section 2.3 of the Agreement, the Option shall terminate at 5:00 p.m., U.S. Eastern time, on the ten-year anniversary of the Option Date.

APREA THERAPEUTICS, INC.

By: _______________________

Name: Oren Gilad


Title: President and CEO


Acknowledgment, Acceptance and Agreement:

By signing below and returning this Award Notice to Aprea Therapeutics, Inc. at the address stated herein, I hereby acknowledge receipt of the Agreement and the Plan, accept the Option granted to me and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.

___________________________

Optionee


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer